Additionally, those studies noted that lenvatinib can regulate cancer immunity in the tumor microenvironment by reducing TAMs and enhance the antitumor effect of anti‐PD‐1 antibodies through activation of the IFN signaling pathway. This evidence concerns the gene IFNA1 and neoplasm.